Common questions, answered from the trial record.

What is sermorelin, and how is it different from growth hormone itself?

Sermorelin is a 29-amino-acid peptide — the N-terminal fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic neuropeptide that normally signals the pituitary to release GH. Growth hormone, by contrast, is a 191-residue protein released by the pituitary itself.

The pharmacological difference is upstream versus downstream. Sermorelin acts upstream: it triggers the body's own pituitary to release endogenous GH in pulses, under intact feedback from somatostatin and IGF-1. Recombinant GH acts downstream: it delivers GH directly to circulation as a sustained exogenous exposure, bypassing pituitary regulation and suppressing endogenous secretion ^[7]. Vitiello 2006 reported that five months of nightly sermorelin doubled 24-hour endogenous GH secretion while keeping IGF-1 within physiological range — feedback-capped output that direct GH delivery does not produce ^[5].

How does sermorelin work at the pituitary?

Sermorelin binds the GHRH receptor (GHRHR), a Class B G-protein-coupled receptor on anterior-pituitary somatotrophs. Receptor activation stimulates Gs-coupled adenylyl cyclase, raising intracellular cAMP. cAMP activates protein kinase A, which phosphorylates CREB, which then drives GH1 gene transcription. In parallel, GHRHR signaling opens L-type voltage-gated calcium channels and triggers exocytosis of pre-formed GH-containing secretory granules. The net result is a measurable GH pulse 30-90 minutes after subcutaneous administration ^[7][17].

What is the half-life of sermorelin, and why is it so short?

Sermorelin's terminal plasma half-life is 11-12 minutes in healthy adults. Peak plasma concentration after subcutaneous administration occurs at 5-20 minutes. Subcutaneous bioavailability is approximately 6%. Total plasma clearance is 2.4-2.8 L/min ^[8].

The half-life is short because the N-terminal tyrosine-alanine bond is a substrate for dipeptidyl peptidase IV (DPP-IV), a circulating serum enzyme. DPP-IV cleavage rapidly inactivates the peptide. This is the engineering problem that later GHRH(1-29) analogs were designed to solve: tesamorelin carries a trans-3-hexenoyl modification on the N-terminal tyrosine, CJC-1295 carries different stabilizing modifications, and both resist DPP-IV cleavage and persist substantially longer in plasma ^[10].

What did the adult research actually measure?

Across the modern adult-aging literature, the headline numbers fall in a recognizable range. In Baker 2012 (152 adults, 20 weeks of 1 mg/day tesamorelin): IGF-1 +117%, body fat -7.4%, lean mass +3.7%, executive function p=0.005 ^[1]. In Vitiello 2006 (89 older adults, 5 months of ~1 mg/night sermorelin): 24-hour GH doubled, IGF-1 +40%, body fat -5%, processing-speed scores +5-7% ^[5]. In Khorram 1997 (19 men and women, 16 weeks of 10 µg/kg [Nle27]GHRH): nocturnal GH and IGF-1 rose, men gained 1.26 kg lean mass, both sexes showed skin-thickness increases ^[3]. In Vittone 1997 (11 elderly men, 6 weeks of 2 mg nightly): nocturnal GH +significant, upper-body strength +significant, IGF-1 not yet significant at 6 weeks ^[2].

The direction of effect is consistent. The magnitudes are statistically robust but clinically modest — not the order-of-magnitude transformations that vendor marketing language sometimes implies.

Why was Geref discontinued — was it safety related?

No. The FDA approvals — 1990 for diagnostic use, 1997 for treatment of pediatric idiopathic GHD — were granted on safety and efficacy data that the regulatory agency accepted. Serono Laboratories voluntarily discontinued commercial production of Geref in 2008. The FDA published the formal withdrawal notice in 2013. The publicly stated reason was business — not a safety signal, not an efficacy failure, not a regulatory action ^[6].

The market context: recombinant human growth hormone (rhGH) had become the standard treatment for pediatric GHD by the early 2000s. rhGH is dosed three to seven times weekly, but it delivers a direct GH effect that is independent of pituitary integrity and has a longer dosing convenience profile than nightly subcutaneous sermorelin. The pediatric pivotal data on sermorelin held up — the commercial market did not.

Is sermorelin available in the US today?

Sermorelin is not currently sold as an FDA-approved finished-drug product in the United States. It is available through 503A compounding pharmacies as an unapproved bulk-substance-derived preparation. The FDA has issued guidance on compounded peptides under Section 503A but has not approved any commercial sermorelin formulation since the 2008 Geref withdrawal.

This site does not sell sermorelin and is not affiliated with any compounding pharmacy or vendor. The site presents the published research literature and the regulatory history; readers seeking compounded-peptide regulatory status should consult primary FDA documents directly.

Is sermorelin banned in sports?

Yes. The World Anti-Doping Agency 2025 Prohibited List places sermorelin explicitly under Section S2.2.4 'Growth hormone-releasing factors,' alongside CJC-1293, CJC-1295, and tesamorelin. The S2 class is prohibited both in-competition and out-of-competition for all WADA-tested sports ^[14].

WADA listing is independent of FDA status. It applies whether the substance is administered by a clinician, self-administered, or obtained through any other route. Athletes subject to WADA testing — Olympic-eligible, NCAA Division I, professional leagues following the WADA code — should treat all GHRH-axis agonists as prohibited substances regardless of their regulatory framing in the broader US market.

How does sermorelin compare to tesamorelin and CJC-1295?

Tesamorelin and CJC-1295 are both stabilized analogs of the same GHRH(1-29) backbone that defines sermorelin. The functional receptor target is the same — GHRHR on pituitary somatotrophs. The downstream signaling cascade is the same — Gs/cAMP/PKA/CREB/exocytosis. The pharmacokinetics diverge meaningfully.

Sermorelin's parent-peptide half-life is 11-12 minutes ^[8]. Tesamorelin and CJC-1295 bear DPP-IV-resistant N-terminal modifications that extend in-vivo activity substantially — tesamorelin to a clinically usable daily dosing window, CJC-1295 (especially in its DAC-modified form) to multi-day persistence. The result is that the modern adult-aging trials with the largest enrollment (Baker 2012, Friedman 2013) used tesamorelin rather than sermorelin itself ^[1][4].

Caution applies when extrapolating tesamorelin or CJC-1295 findings to sermorelin: the receptor and signaling are shared, but the achievable plasma-exposure profile diverges, and tesamorelin's longer persistence may carry different pharmacological consequences than sermorelin's pulsatile, rapidly-cleared exposure.

What did the original pediatric trials show?

The pediatric idiopathic-GHD evidence base, reviewed in detail by Prakash and Goa 1999, supports the 1997 FDA pediatric approval ^[6]. Once-daily subcutaneous 30 µg/kg at bedtime sustained height-velocity gains over 12 months. Growth velocities averaged 8-10 cm/year on treatment versus baseline 4-5 cm/year — roughly twofold acceleration. Efficacy reportedly continued out to 36 months in extended follow-up ^[12].

The diagnostic indication used single intravenous sermorelin 1 µg/kg, which reliably triggered a measurable pituitary GH peak in children with intact somatotroph function. The most common adverse effects were transient facial flushing and injection-site reactions. Multi-year follow-up showed no evidence of pituitary exhaustion or receptor tachyphylaxis.

Does sermorelin research support cognitive benefits?

The signal is real but modest. Baker 2012 reported improved executive function in 152 adults receiving 20 weeks of 1 mg/day tesamorelin (p=0.005, f=0.37), with comparable benefit in healthy and mild-cognitive-impairment participants ^[1]. Vitiello 2006 reported 5-7% improvements in psychomotor and perceptual processing-speed scores in 89 older adults over 5 months of nightly sermorelin ^[5].

Friedman 2013 added neurochemical evidence: 20 weeks of 1 mg/day tesamorelin elevated GABA in three brain regions (P<0.04), raised NAAG in dorsolateral frontal cortex (P=0.03), and decreased myo-inositol in posterior cingulate (P=0.002) on MR spectroscopy ^[4]. These changes are consistent with a putative neuroprotective signature.

A 2024 preclinical report in 5xFAD Alzheimer's-model mice showed that MR-409 (a stabilized GHRH agonist directly descended from sermorelin's backbone) reduced brain amyloid-β deposition, astrogliosis, neuron loss, and Tau phosphorylation while elevating BDNF ^[13]. Preclinical signals are not human outcomes, but the GHRH-axis cognitive-effects literature has grown enough across two decades to be taken seriously rather than dismissed.

What side effects appear in the controlled trials?

The most rigorously characterized safety dataset is Baker 2012, in which 137 completers received 20 weeks of 1 mg/day subcutaneous tesamorelin. Treatment-emergent adverse-event rate was 68% on active versus 36% on placebo, dominated by mild injection-site reactions and arthralgias. Seventeen percent of treated participants required a dose adjustment. No serious cardiovascular events were reported ^[1][9].

The pediatric trial record reports transient facial flushing and injection-site reactions as the most common adverse effects, with no evidence of pituitary exhaustion or receptor tachyphylaxis on multi-year follow-up ^[6][12]. Theoretical concerns about acute GH/IGF-1 elevation — insulin resistance, edema, carpal tunnel syndrome, tumor-growth promotion — have not been documented in the controlled trial record, in which IGF-1 elevation stayed within physiological range.

Is there evidence of tolerance or tachyphylaxis?

The published trial record does not show meaningful tachyphylaxis at therapeutic research doses. Pediatric trials reviewed by Prakash and Goa reported sustained efficacy out to 36 months on once-daily dosing. Adult trials at 5 to 20 weeks (Vittone 1997, Khorram 1997, Vitiello 2006, Baker 2012) reported endpoint effects that grew or held over the trial duration rather than fading.

The mechanistic argument is that intact somatostatin and IGF-1 feedback under GHRH agonism prevent the chronic pituitary overstimulation that would drive desensitization. Walker 2006 framed this as one of the central pharmacological arguments for GHRH-axis stimulation over direct rhGH delivery ^[7].

Does sermorelin affect sleep?

The evidence is mixed and modest. Endogenous GH secretion in healthy adults is concentrated during slow-wave sleep (SWS), and the bedtime-dosing convention for chronic sermorelin trials was designed to align with that natural peak.

Vitiello 2006 — which measured sleep architecture explicitly — found that five months of nightly sermorelin doubled 24-hour GH secretion and raised IGF-1 ~40% but did not significantly alter SWS architecture in the 89 older-adult cohort ^[5]. In other words, sermorelin amplified the GH pulse without measurably restructuring the underlying sleep stage pattern. This does not rule out subjective sleep-quality effects on a longer time scale, but the controlled-trial evidence does not support a strong claim that sermorelin restores aging-related SWS decline.

Where can I read the primary research?

Every claim on this site cites a primary source on /references. PMID-linked PubMed entries, DOI-resolved journal pages, and PMC full-text links are provided where available. The eighteen citations cover the modern adult-aging trial record (Vittone 1997, Khorram 1997, Vitiello 2006, Baker 2012, Friedman 2013), the pediatric foundational review (Prakash and Goa 1999), the pharmacokinetic data (Serono/RxList prescribing-information summary), the regulatory context (FDA history, 2025 WADA Prohibited List), and the recent 2024-2025 reviews (Schally 2024, Granata 2024, Cai 2024 MR-409 preclinical) that frame sermorelin as the prototype of an expanding GHRH-analog pipeline.